Skip to main content
Caplight Logo









Newrotex

Newrotex

Private
OxfordHealthcare & Life Scienceshttps://newrotex.com/

Last Round

Grant

Jan 1, 2024

Total Funding Raised

$6.03M

Company Overview

Newrotex is a surgical devices company that develops silk-based medical solutions for peripheral nerve repair.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology, Clinical Trials, Advanced Materials

Business Model

B2B

Customer Profile

Government Contracts, Hardware Sales, Services & Consulting

AI Layer

Non-AI

Keywords

peripheral nerve repairnerve regenerationnerve conduitautograft alternativesilk-based medical deviceregenerative medicinelarge-gap nerve injurytissue engineeringnerve guidance conduitspider silk implantbiomaterialsclinical-stage biotechreconstructive surgerymedical device manufacturingISO 13485

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Newrotex Comparables

Compare Newrotex with similar companies based on industry and business-model similarity.

Newrotex comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
ReNerve Limited
83%
Axonova Medical
81%
Auxilium Biotechnologies
78%

Newrotex Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJan 1, 2024
AcceleratorOct 11, 2023
GrantMar 22, 2023
GrantAug 1, 2022
GrantMay 1, 2020
Grant
May 1, 2020

Key People

Founding team and executive leadership

Alex Woods

Co-Founder & CEO

Founding Team

Katie Slater

Chief Operating Officer

Executive Team

Newrotex Investors

Notable investors and investment history

Newrotex investors
InvestorRounds
European Innovation Council FundGrant
Horizon Europe GuaranteeGrant
MedTech InnovatorAccelerator
Innovate UKGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 17, 2026

    Monthly visitors grew 210% MoM, reaching 1.7K.

  • Nov 8, 2025

    Monthly visitors grew 710% MoM, from 134 to 1.1K.

Newrotex Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Newrotex Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Newrotex's valuation, stock price, and market status.

Firmographic Details

HeadquartersOxford
Employee Range8
Year Founded2019
Last FundingJan 1, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?